Ophthalmic Devices (IOLs, Contact Lenses, and Lasers): Global Regulation and Registration

For every regulator below we answer the three questions ophthalmic device teams ask first: what class is my product, how long will registration take, and what will it cost. Start with our pricing calculator for per-market fees and timelines.

What are ophthalmic devices?

Ophthalmic medical devices are the instruments, implants, and materials used to diagnose and treat conditions of the eye. The category spans intraocular lenses (IOLs) implanted during cataract surgery, contact lenses, ophthalmic surgical lasers including LASIK and photocoagulation systems, diagnostic imaging such as optical coherence tomography (OCT), fundus cameras, slit lamps and tonometers, ophthalmic viscosurgical devices (OVDs) used to protect tissue during surgery, and the surgical instruments and phaco systems used in the operating room. What ties them together is the regulator: in the United States they share their own dedicated rulebook, 21 CFR Part 886.

Two boundaries matter. Ophthalmic drugs such as eye drops, intravitreal injections, and most glaucoma and dry-eye therapies are regulated as medicines, not devices, even though they treat the same organ; a preloaded injector or a drug-eluting insert can become a combination product. And AI that autonomously reads retinal images to screen for diabetic retinopathy or glaucoma is regulated as software as a medical device, covered on our SaMD page, while the camera or OCT scanner that captures the image stays on this page as hardware.

Every jurisdiction draws the classification line differently. The same intraocular lens is a Class III device demanding a full premarket approval in the United States but a Class IIb device under EU MDR, which is why a market-by-market classification analysis is the first deliverable of any serious ophthalmic program. Every cost below has two parts: the government fee, and our own flat annual service fee per market, from US$1,000 per year in the US (device listing and US Agent representation) and from US$2,000 per year in most other markets. Exact current figures live in our pricing calculator.

FDA ophthalmic device regulation (United States)

FDA regulates ophthalmic devices under 21 CFR Part 886 through the same risk-based framework as other devices, with a dedicated Ophthalmic Devices advisory panel for novel technologies. Risk drives everything: most diagnostic and surgical instruments clear as Class II, while implants and surgical materials that enter the eye, such as IOLs and OVDs, sit in Class III.

• Classification. Most diagnostic and surgical ophthalmic devices, including slit lamps, OCT scanners, phaco systems, many surgical lasers, and daily-wear soft contact lenses, are Class II and clear through a 510(k). Intraocular lenses and extended-wear contact lenses are Class III and require a premarket approval (PMA); novel devices without a predicate go the De Novo route. Ophthalmic viscosurgical devices (OVDs) are the counterintuitive case: although they are removed at the end of surgery, FDA regulates them as Class III intraocular fluids under 21 CFR 886.4275, reaching the market through a PMA supported by clinical data rather than a 510(k). In the US, contact lenses also carry a prescription requirement, whether they are corrective or purely cosmetic.
• Timeline. A 510(k) typically runs 3 to 9 months end to end including preparation and FDA interaction; a PMA for an IOL or other Class III device is a multi-year program built around clinical data. A Pre-Sub meeting adds a few weeks up front and routinely saves review cycles later.
• Cost. Government fees: US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses) plus US$11,423 per year in establishment registration; PMA review fees run substantially higher. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

Start from our United States market page for the full FDA pathway.

Intraocular lenses (IOLs): a Class III device in the US

The intraocular lens is the highest-risk ophthalmic device most manufacturers will register, and it drives the toughest evidence demands in the category. In the United States an IOL is a Class III device that needs a PMA supported by clinical outcomes data; under EU MDR it is Class IIb; and in Brazil, the Gulf, and much of Asia-Pacific it lands in the upper risk classes with correspondingly deeper technical files. Premium lenses, including multifocal, toric, extended-depth-of-focus, and light-adjustable intraocular lenses, raise the bar further, because every added optical claim needs its own clinical support. We build the ISO 11979 optical and clinical evidence package once and reuse it across markets, so a monofocal or premium IOL platform is not re-tested from scratch in every jurisdiction.

EU MDR ophthalmic device classification and CE marking

Under EU MDR (Regulation 2017/745), ophthalmic devices are classified by rule, a notified body sits in the middle of your timeline for anything above Class I, and implants in the eye carry some of the heaviest documentation in the category.

• Classification. Intraocular lenses are Class IIb under MDR (Rule 8, implantable); contact lenses classify by duration of wear under Annex VIII Rule 5 — daily-wear corrective lenses are Class IIa, while lenses intended for long-term continuous wear are Class IIb (MDCG 2021-24). Active surgical lasers are typically Class IIb, and diagnostic devices such as OCT scanners and fundus cameras are generally Class IIa. Genuinely Class I ophthalmic devices, such as some non-active instruments, are the exception, and each higher class pulls in a notified body.
• Timeline. Plan 9 to 18 months with a notified body for a first Class IIb certification, driven by notified body capacity and the maturity of your technical documentation and clinical evaluation.
• Cost. There is no central government fee; the money goes to the notified body, typically EUR 30,000 to EUR 70,000 across a first Class IIa or IIb certification cycle, higher for Class III, plus annual surveillance, and to building MDR-grade documentation. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

See the European Union market page for the MDR route and notified body strategy.

Ophthalmic device registration in Brazil and Latin America (ANVISA)

Brazil anchors any Latin American strategy. ANVISA classifies ophthalmic devices from Class I to IV and requires a local representative; we act as Brazil Registration Holder without taking control of your registration. Mexico's COFEPRIS is the region's second gate.

• Classification. ANVISA's risk rules track the IMDRF model: lower-risk instruments and accessories qualify for the streamlined notificação route, while intraocular lenses and other implantable or high-risk ophthalmic devices require full registro with deeper technical and clinical evidence.
• Timeline. Notification is typically a matter of weeks; Class III-IV registration plans for 6 to 12 months. In Mexico, COFEPRIS runs 6 to 12 months on the standard route, faster where reliance on FDA or CE approvals applies.
• Cost. ANVISA government fees: R$1,406 to notify a lower-risk product; Class III-IV family registration runs R$8,510 to R$19,856, plus a one-time international B-GMP certification of R$72,805 where required for higher-risk manufacturing. COFEPRIS charges MX$16,499 to MX$30,798 per product by class. Our registration service starts at US$2,000 per year, and US$3,000 for high-risk classes such as IOLs.

Start with the Brazil market page; labeling, instructions for use, and submissions are prepared natively in Portuguese and Spanish.

Ophthalmic device registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas ophthalmic manufacturers enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a strong FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN, including Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where reliance-friendly frameworks make each additional market incremental rather than a new program. Japan and Korea are the region's big mature prizes with their own systems and languages. China is the largest market but the hardest entry, with local type testing and the longest timelines, so treat it as its own program when the business case justifies it, not as a default stop.

• Classification. Singapore's HSA uses risk classes A through D, and ASEAN members track the same IMDRF-style model: IOLs and surgical implants land in the upper classes (C or D), contact lenses and lasers in the middle, and simple diagnostic instruments low. Japan classifies against JMDN codes, Korea's MFDS uses Classes I-IV, and China places most implantable and surgical ophthalmic devices in Class II or III.
• Timeline. HSA abridged evaluation with a reference approval closes in 2 to 6 months; ASEAN registrations typically run 3 to 9 months per market on the back of the same dossier. Japan plans for 9 to 14 months via PMDA, Korea 6 to 12 months including KGMP, and China 12 to 24 months including type testing.
• Cost. Singapore's government fees are light: an SGD 560 application plus SGD 2,010 to SGD 6,250 evaluation by class, with ASEAN peers similar (Malaysia MYR 500 to MYR 3,000; Thailand THB 3,100 to THB 21,000). Japan's PMDA approval review fees start around JPY 1.5 million for a me-too device and rise to several million yen for improved and novel devices, and China's NMPA fees for imported Class II-III run roughly RMB 210,000 to RMB 310,000 before type testing. Our registration service starts at US$2,000 per year across Singapore and ASEAN, and is quoted flat per market on the same model for Japan, Korea, and China.

See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

Ophthalmic device registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing device regions in our portfolio, and its regulators are built around reliance: a strong FDA, CE, or other reference approval does most of the work if the dossier is assembled correctly. SFDA regulates ophthalmic devices on the IMDRF model and requires a local Authorized Representative.

• Classification. SFDA classifies ophthalmic devices into risk classes A through D, mirroring your reference-market class in most cases; the UAE's MOHAP and other MENA authorities lean on the reference approval's classification, so an IOL cleared as Class III in the US and IIb in the EU is registered as a high-risk device across the Gulf.
• Timeline. With a reference approval in hand, SFDA marketing authorization typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer.
• Cost. Government fees across the Gulf are modest, generally a few thousand US dollars' equivalent per authority, so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote MENA registration programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages.

Evidence, quality system, and lifecycle

Ophthalmic devices touch the eye directly, so the evidence bar is built around biocompatibility, optical performance, and clinical safety. We set up an ISO 13485 quality system, plan biocompatibility to ISO 10993 for anything that contacts ocular tissue, and build optical and clinical evidence against the recognized ophthalmic standards, including the ISO 11979 series for intraocular lenses, ISO 11980 for contact lenses, and photobiological and laser-safety testing (IEC 60601 electrical safety and IEC 60825 laser safety) for energy-based devices. Clinical evidence for IOLs and premium lenses is planned once for reuse across FDA, EU MDR, and APAC submissions. Connected diagnostic devices, such as networked OCT platforms, cloud-linked fundus cameras, and image-management systems, also need cybersecurity documentation that satisfies FDA and EU MDR expectations. After launch, complaint handling, field-safety reporting, and change assessments keep every registration current.

One program, every major market

A global ophthalmic program is a sequencing problem: pick the anchor market, build the clinical and optical evidence once, and reuse classification analyses, test data, and QMS artifacts everywhere else. We run the full program from a single team, covering strategy, submissions, in-country representation, and post-market maintenance, with transparent government fees and timelines in our pricing calculator.